Aptevo Therapeutics Reports on Shareholder Votes

TL;DR

APVO filed an 8-K for shareholder votes - no details yet, but it happened.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on October 25, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as a formal notification to the SEC regarding these proceedings.

Why It Matters

This filing indicates that Aptevo Therapeutics held a shareholder meeting where votes were cast on important company matters, a standard but necessary disclosure for public companies.

Risk Assessment

Risk Level: low — The filing is a procedural disclosure of shareholder votes and does not contain new financial or operational information that would immediately impact risk.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• October 25, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20241025.htm (8-K) — 53KB
• 0000950170-24-117439.txt ( ) — 168KB
• apvo-20241025.xsd (EX-101.SCH) — 25KB
• apvo-20241025_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 25, 2024, Aptevo Therapeutics Inc. (the "Company") held its 2024 Special Meeting of Stockholders (the "Special Meeting"), at which a quorum was present. Stockholders considered three proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on October 3, 2024 (the "Proxy Statement"). The final voting results with respect to each of the proposals acted upon at the 2024 Special Meeting are set forth below. Proposal 1: Approval of the stock issuance and warrant proposal The issuance of more than 19.99% of the Company's outstanding Common Stock, issuable upon the exercise of Common Warrants issued pursuant to that certain Securities Purchase Agreement, dated as of September 16, 2024, which includes an exercise price adjustment provision in the event of an issuance of common stock or common stock equivalent, an option to purchase common stock or common stock equivalent, change in price of common stock or common stock equivalent or other such event as described in the Common Warrants and to approve the amendment of certain existing warrants to include the same exercise price adjustment provisions and the repricing of such existing warrants pursuant to the Securities Purchase Agreement, was approved based on the following: FOR AGAINST ABSTAIN BROKER NON-VOTES 593,301 412,901 5,355 2,268,029 Proposal 2: Approval of the Company's Amended and Restated Certificate of Incorporation An amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company common stock at a ratio in the range of 1-for-5 to 1-for-37, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in i

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: October 25, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR